Evidence map›Paper›PMID 39656784›Full record

Trial reportRheumatology (Oxford, England)2025

A multivariable prediction model to identify anti-CCP positive people in those with non-specific musculoskeletal symptoms in primary care.

Heidi J Siddle, Michelle Wilson, Jacqueline L Nam, Leticia Garcia-Montoya, Laurence Duquenne, Kulveer Mankia, Paul Emery, Elizabeth M A Hensor

Abstract readClinical Trial
In one paragraph

Trial report in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Identifying people at risk of rheumatoid arthritis in primary care: a qualitative study.The British journal of general practice : the journal of the Royal College of General Practitioners · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Heidi J SiddleLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.ORCID 0000-0002-6015-332X
Michelle WilsonLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.ORCID 0000-0001-7556-1599
Jacqueline L NamLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.ORCID 0000-0003-4944-7922
Leticia Garcia-MontoyaLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.ORCID 0000-0002-1806-7532
Laurence DuquenneLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.ORCID 0000-0001-7631-0986
Kulveer MankiaLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.ORCID 0000-0002-7945-6582
Paul EmeryLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.ORCID 0000-0002-7429-8482
Elizabeth M A HensorLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.ORCID 0000-0002-5245-4755

Funding

AstraZenecaDepartment of Health and Social CareHealth Education EnglandLeeds Biomedical Research Centre 2017-2022Leeds Biomedical Research Centre IS-BRC-1215-20015; 2022-2027Leeds Biomedical Research Centre NIHR203331National Institute for HealthNational Institute for Health and Care ResearchSenior Clinical Lecturer ICA-SCL-2018-04-ST2-004
6 · The paper itself

Abstract

objectivesWe aimed to develop a prediction model identifying people presenting to primary care with musculoskeletal symptoms likely to be anti-CCP positive and therefore at risk of developing RA.

methodsParticipants aged ≥16 years, with new-onset non-specific musculoskeletal symptoms and no history of clinical synovitis, completed a symptom questionnaire and had an anti-CCP test. Model development used LASSO-penalized logistic regression, performance was assessed using area under the receiver operating characteristic curve (AUROC) and decision curve analysis, model over-fit was estimated using bootstrapping and cross-validation. Participants were followed-up at 12 months for RA or seronegative/undifferentiated inflammatory arthritis diagnosis.

resultsAnalysis included 6879 participants; 203 (2.95%) of whom were anti-CCP positive. Eleven predictors were retained: male sex, first-degree relative with RA, ever smoked and joint pain in: back, neck, shoulders, wrists, hands/fingers, thumbs, knees, feet/toes. AUROC was 0.65 (95% CI 0.61, 0.69, optimism = 0.03). Using a 4% decision threshold, the model recommended an anti-CCP test in 1288 (18.7%) participants, 78 (6.1%) of whom were anti-CCP positive, compared with 125/5591 (2.2%) below the threshold. Net benefit was 0.0040 (0.0020 corrected). Forty-eight participants were diagnosed with inflammatory arthritis/RA within 12 months. Of those who were above the threshold and anti-CCP positive, 32.1% developed inflammatory arthritis/RA compared with 0.4% of those who were anti-CCP negative. Of those below the threshold, 0.3% were diagnosed with inflammatory arthritis/RA.

conclusionsTargeted anti-CCP testing in primary care may aid earlier identification of people at risk of RA, prompting specialist referral to rheumatology for earlier diagnosis and initiation of disease-modifying therapy.

Indexed as

Anti-Citrullinated Protein AntibodiesArthritis, RheumatoidAdultAgedFemaleHumansMaleMiddle AgedPredictive Value of TestsPrimary Health CareRisk AssessmentRisk FactorsAnti-Citrullinated Protein Antibodiesanti-cyclic citrullinated peptide (anti-CCP) antibodiesat risk of rheumatoid arthritisinflammatory arthritismusculoskeletal symptomsprediction model

Identifiers

PMID39656784
PMCPMC12107024

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.